ImmuPharma plc (LON:IMM – Get Free Report) fell 11.7% on Thursday . The stock traded as low as GBX 3.75 ($0.05) and last traded at GBX 3.80 ($0.05). 14,936,349 shares traded hands during mid-day trading, a decline of 25% from the average session volume of 19,799,125 shares. The stock had previously closed at GBX 4.31 ($0.05).
ImmuPharma Stock Performance
The firm has a market cap of £16.58 million, a PE ratio of -6.74 and a beta of 1.53. The stock has a fifty day moving average price of GBX 2.77 and a 200-day moving average price of GBX 2.04.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- How is Compound Interest Calculated?
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- 3 Monster Growth Stocks to Buy Now
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
